Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 130-136, August 2009

Cancer Immunotherapy

  • Philip J. Bergman, DVM, MS, PhD, DACVIM-Oncology

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Philip J. Bergman, DVM, MS, PhD, Dipl. ACVIM-Oncology, 80 Business Park Dr, Ste 110, Armonk, NY 10504

BrightHeart Veterinary Centers Armonk, NY, USA; and the Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The immune system is generally divided into 2 primary components: the innate immune response, and the highly specific but more slowly developing adaptive or acquired immune response. Immune responses can be further separated by whether they are induced by exposure to a foreign antigen (an “active” response) or whether they are transferred through serum or lymphocytes from an immunized individual (a “passive” response). The ideal cancer immunotherapy agent should be able to discriminate between cancer and normal cells (ie, specificity), be potent enough to kill small or large numbers of tumor cells (ie, sensitivity), and lastly be able to prevent recurrence of the tumor (ie, durability). Tumor immunology and immunotherapy is one of the most exciting and rapidly expanding fields at present.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1938-9736(09)00047-6

doi:10.1053/j.tcam.2009.06.001

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 130-136, August 2009